JMP reiterates Celgene at outperform

Celgene Corp. was reiterated by JMP Securities analyst Charles C. Duncan at market outperform. Celgene's third-quarter earnings exceeded expectations with stronger-than-anticipated Revlimid and Thalomid sales, with total revenues of $245 million, above estimates of $234 million. Shares of the Summit, N.J.-based pharmaceutical company were up 69 cents, or 1.39%, at $40.33 on volume of 5,377,827 shares versus the three-month running average of 3,578,230 shares. (Nasdaq: CELG)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.